Table 1 Logistic Regression of Clinical/Transplantation Factors on High T-SPOT.CMV Counts.

From: The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O009-O172)

 

Univariable Analysis

Multivariable Analysis

 

Variable

Category

OR (95% CI)

P-value

Variable

Category

OR (95% CI)

P-value

pp65

        
 

Any CMV day 0-100 post-HCT

No

1

 

Any CMV day 0-100 post-HCT

No

1

 
  

Yes

3.01 (1.44–6.29)

0.003

 

Yes

7.11 (2.52–20.1)

<0.001

 

Donor CMV serostatus

-

1

 

Donor CMV serostatus

-

1

 
  

+

5.57 (2.50–12.4)

<0.001

 

+

7.73 (2.95–20.2)

<0.001

IE-1

        
 

Any CMV day 0-100 post-HCT

No

1

 

Any CMV day 0-100 post-HCT

No

1

 
  

Yes

2.62 (1.01–6.84)

0.048

 

Yes

3.82 (1.30–11.2)

0.02

 

Donor CMV serostatus

-

1

 

Donor CMV serostatus

-

1

 
  

+

4.31 (1.64–11.3)

0.003

 

+

5.68 (1.97–16.3)

0.001

 

Age

<=60 yr

1

 

Age

<=60 yr

1

 
  

>60 yr

0.26 (0.07–0.93)

0.04

 

>60 yr

0.23 (0.06–0.92)

0.04

  1. Any CMV defined as any positive CMV DNA PCR test including those below the assay limit of quantitation (50 IU/mL).
  2. Multivariable pp65 models included GVHD prophylaxis as an additional adjustment variable which was significant in the univariable models but not in the final multivariable models.
  3. CI confidence interval, CNI calcineurin inhibitor, GVHD graft-versus-host disease, MMF mycophenolate, MTX methotrexate, OR odds ratio, PTCy post-transplantation cyclophosphamide, siro sirolimus.
Back to article page